Group 1 - The core viewpoint of the report is to summarize the sponsorship activities and compliance of Huatai United Securities in relation to the initial public offering (IPO) of Jiahe Meikang (Beijing) Technology Co., Ltd. on the Sci-Tech Innovation Board [1][3][10] - The issuer, Jiahe Meikang, has a registered capital of 137,585,598 yuan and was listed on December 14, 2021, with the stock code 688246.SH [1][3] - The total net proceeds from the IPO amounted to 1,240,457,179.15 yuan, which were allocated to various projects including electronic medical record development and operational funds [4][10] Group 2 - During the continuous supervision period, the sponsor conducted semi-annual inspections of the use and storage of raised funds, ensuring compliance with regulations [3][4] - The sponsor issued a total of 18 verification opinions regarding the issuer's use of raised funds and did not issue any dissenting opinions [4][10] - The issuer's shareholders, specifically the Xianning Kaixuan Opportunity Growth Fund, failed to timely fulfill commitments related to share reduction, leading to regulatory actions [5][7] Group 3 - The issuer discovered accounting errors in the financial statements for 2022 and 2023, which were corrected through retrospective adjustments approved by the board [10][11] - The sponsor confirmed that the issuer complied with relevant regulations in the use of raised funds and maintained proper disclosure practices [10][12] - As of December 31, 2024, the raised funds had not been fully utilized, and the sponsor will continue to oversee the usage until completion [12]

保荐机构知悉上述情况后，了解到公司归母净利润、归母扣非净利润2024 年出现亏损的主要原因包括：（1）收入及成本的影响：收入端，受整体经济环 境及医疗行业环境的影响，部分客户需求释放递延、招投标节奏滞后、实施交付 周期延长，导致当期订单有所下降，2024年收入减少；成本端，受行业环境影响， 部分客户的项目验收周期延长，导致发生更多成本，且2024年无法签约项目结转 成本金额较上期增加；（2）减值准备的影响：公司结合经营管理情况、行业环 根据《证券法》《证券发行上市保荐业务管理办法》和《上海证券交易所科 创板股票上市规则》等有关法律、法规的规定，华泰联合证券有限责任公司（以 下简称"华泰联合证券"或"保荐机构"）作为嘉和美康（北京）科技股份有限 公司（以下简称"嘉和美康"、"公司"或"发行人"）首次公开发行股票的保 荐机构，对嘉和美康进行持续督导，并出具 2024 年度（以下简称"报告期"）持 续督导跟踪报告： 一、保荐机构和保荐代表人发现的问题及整改情况 （一）公司业绩由盈转亏 2024年公司实现营业收入59,194.43万元，较上年同期收入减少14.85%，实现 归属于上市公司股东的净利润-25,611.7 ...

二、保荐机构基本情况 保荐总结报告书 华泰联合证券有限责任公司 关于嘉和美康（北京）科技股份有限公司 首次公开发行股票并在科创板上市 之保荐总结报告书 | 保荐机构名称 | 华泰联合证券有限责任公司 | | --- | --- | | 保荐机构编号 | Z26774000 | 1、保荐总结报告书和证明文件及其相关资料的内容不存在虚假记载、误导 性陈述或重大遗漏，保荐机构及保荐代表人对其真实性、准确性、完整性承担法 律责任。 一、保荐机构及保荐代表人承诺 2、本机构及本人自愿接受中国证券监督管理委员会（以下简称"中国证监 会"）、上海证券交易所对保荐总结报告书相关事项进行的任何质询和调查。 3、本机构及本人自愿接受中国证监会按照《证券发行上市保荐业务管理办 法》的有关规定采取的监管措施。 | 情况 | 内容 | | --- | --- | | 保荐机构名称 | 华泰联合证券有限责任公司 | | 注册地址 | 深圳市前海深港合作区南山街道桂湾五路 128 号前海深港基金小 | | | 镇 栋 B7 401 | | 主要办公地址 | 北京市西城区丰盛胡同 22 号丰铭国际大厦 A 座 6 层 | | 法定代表人 | ...

Group 1 - The DRG/DIP concept declined by 3.30%, ranking among the top declines in the concept sector, with notable declines in companies such as Chuangying Huikang, ST Yilianzhong, and Jiahe Meikang [1][2] - The DRG/DIP concept experienced a net outflow of 4.92 billion yuan in main funds, with 19 stocks seeing net outflows, and 13 stocks with outflows exceeding 10 million yuan [2] - The stock with the highest net outflow was Donghua Software, with a net outflow of 1.26 billion yuan, followed by Chuangying Huikang, Weining Health, and Dian Diagnosis [2][3] Group 2 - The top stocks with net outflows in the DRG/DIP concept included Donghua Software (-3.97%), Chuangying Huikang (-6.76%), and Weining Health (-4.60%) [2][3] - Conversely, the stocks with net inflows included Huaping Co., Guoke Hengtai, and Wanda Information, with net inflows of 238.84 million yuan, 166.15 million yuan, and 121.00 million yuan respectively [2]

证券代码：688246 证券简称：嘉和美康 为了维护全体股东的合法权益，确保股东大会的正常秩序和议事效率，保证 大会的顺利进行，根据《中华人民共和国公司法》《中华人民共和国证券法》《上 市公司股东会规则》以及《公司章程》《股东大会议事规则》等相关规定，特制 定嘉和美康（北京）科技股份有限公司（以下简称"公司"）2024 年年度股东 大会会议须知： 一、为确认出席大会的股东或其代理人或其他出席者的出席资格，会议工作 人员将对出席会议者的身份进行必要的核对工作，请被核对者给予配合。 二、为保证本次大会的严肃性和正常秩序，切实维护股东的合法权益，务必 请出席大会的股东或其代理人或其他出席者准时到达会场签到确认参会资格，在 会议主持人宣布现场出席会议的股东和代理人人数及所持有的表决权数量之前， 会议登记应当终止。 三、会议按照会议通知上所列顺序审议、表决议案。 四、股东及股东代理人参加股东大会依法享有发言权、质询权、表决权等权 利。股东及股东代理人参加股东大会应认真履行其法定义务，不得侵犯公司和其 他股东及股东代理人的合法权益，不得扰乱股东大会的正常秩序。 五、要求发言的股东及股东代理人，应提前在股东大会签到处进行登 ...

嘉和美康（北京）科技股份有限公司 证券代码：688246 证券简称：嘉和美康 嘉和美康（北京）科技股份有限公司 2024 年年度股东大会会议资料 2025 年 5 月 27 日 | 2024 | 年年度股东大会会议须知 | 2 | | --- | --- | --- | | 2024 | 年年度股东大会会议议程 | 4 | | 2024 | 年年度股东大会会议议案 | 6 | | 议案一：关于公司 2024 | 年度董事会工作报告的议案 6 | | | 议案二：关于公司 2024 | 年度财务决算报告的议案 7 | | | 议案三：关于公司 2024 | 年度利润分配预案的议案 8 | | | 议案四：关于公司 2024 | 年年度报告及摘要的议案 9 | | | 议案五：关于公司续聘 | 2025 年度审计机构的议案 10 | | | 议案六：关于公司 2025 | 年度董事薪酬的议案 11 | | | 议案七：关于变更公司注册资本、修订《公司章程》及相关制度的议案 | | 12 | | 议案八：关于公司未弥补亏损达到实收股本三分之一的议案 13 | | | | 议案九：关于公司 2024 | 年度监事会工 ...

Investment Rating - The report maintains a "Buy" rating for the company [6][7]. Core Views - The company faces short-term pressure on performance due to industry conditions, high R&D investments, and losses from subsidiaries. Revenue for 2024 is projected at 592 million, down 14.9% year-on-year, with a net loss of 256 million [6]. - The company is a leader in electronic medical records and medical big data solutions, with a strong market presence and ongoing development of AI technologies [6][7]. - The report anticipates a recovery in performance starting in 2027, driven by new product launches and an improving market environment, projecting a target market value of 61.8 billion with a 56% upside potential [6][7]. Financial Data and Earnings Forecast - Total revenue is expected to be 725 million in 2025, with a growth rate of 22.4%, and projected to reach 1,105 million by 2027 [5]. - The company is expected to return to profitability with a net profit of 34 million in 2025, increasing to 161 million by 2027 [5]. - Gross margin is forecasted to improve from 41.1% in 2025 to 45.1% in 2027, indicating a recovery in operational efficiency [5]. Company Overview - The company reported a total revenue of 1.01 billion in Q1 2025, reflecting a 17.4% decline year-on-year, with a net loss of 17 million [6]. - The report highlights the company's strategic focus on maintaining high R&D investment while controlling other expenses, with R&D expenses projected at 152 million in 2025 [6][11]. - The company has introduced new technologies in electronic medical records, enhancing its competitive edge in the market [6].

Summary of Key Points Core Viewpoint - The major shareholder, Hongyun Jiukang Data Technology (Beijing) Co., Ltd., plans to reduce its stake in Jiahe Meikang (688246.SH) due to liquidity needs, intending to sell up to 1,375,855 shares, which represents no more than 1% of the company's total share capital [1][2]. Group 1: Shareholder Information - Hongyun Jiukang holds 9,861,786 shares, accounting for 7.17% of the total shares of Jiahe Meikang [2][4]. - The shares to be sold were acquired before the IPO and have been tradable since December 14, 2022 [2][4]. Group 2: Reduction Plan Details - The planned reduction will occur through centralized bidding, with a timeframe from June 3, 2025, to September 2, 2025 [2]. - The reduction is motivated by the shareholder's liquidity requirements [2]. Group 3: Company Background - Jiahe Meikang was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on December 14, 2021, with an initial offering price of 39.50 yuan per share [5]. - The company raised a total of 1.362 billion yuan through its IPO, with a net amount of 1.24 billion yuan after deducting issuance costs [5]. - The funds raised were intended for various projects, including electronic medical record development and data center upgrades [5].

Group 1 - Baichuan Energy plans to reduce its shareholding by up to 26.82 million shares, accounting for 2% of the total share capital, due to personal investment and funding needs [1] - Jinhong Gas intends to distribute a cash dividend of 1.00 yuan per 10 shares, with the record date on May 15, 2025 [2] - Jiahe Meikang's shareholder plans to reduce its stake by up to 1% of the total share capital due to liquidity needs [2][3] Group 2 - Jiadu Technology will cancel 10.20 million repurchased shares, reducing its total share capital from 2.143 billion shares to 2.133 billion shares [4] - ILE Home's shareholder plans to reduce its stake by up to 154,250 shares, accounting for 0.4778% of the total share capital, due to funding needs [5] - Lai Yifen has fully removed related batches of its honey date dumpling products from shelves due to consumer health concerns [6][7] Group 3 - CATL's vice chairman Li Ping and spouse plan to donate 4.05 million shares to Fudan University for establishing a research fund, reducing Li Ping's shareholding from 4.58% to 4.48% [8] - Shuanghuan Transmission's shareholders completed their reduction plan, selling a total of 6.69 million shares, accounting for 0.789% of the total share capital [9] - Chengfei Integration reported no significant changes in its business operations or external environment despite stock price fluctuations [10] Group 4 - Guizhou Tire's controlling shareholder plans to increase its stake by no less than 50 million yuan and no more than 100 million yuan within six months [11] - *ST Youshu's application to revoke the delisting risk warning has been approved, and its stock will resume trading under a new name [13] - Jingwei Huikai's shareholders plan to reduce their stake by up to 3% of the total share capital due to funding needs [14] Group 5 - Hualan Biological's major shareholder plans to reduce its stake by up to 3% of the total share capital due to funding needs [15] - Huyou Pharmaceutical's shareholder plans to reduce its stake by up to 2.997% of the total share capital due to funding needs [16] - Dongpeng Holdings' shareholders plan to reduce their stake by up to 1.5% of the total share capital due to funding needs [17] Group 6 - Keleke's controlling shareholder plans to reduce its stake by up to 3% of the total share capital due to funding needs [18] - Dongfang Ocean's major shareholder plans to reduce its stake by 1% of the total share capital due to investor redemption requests [19] - Yisheng Shares reported a sales revenue of 141 million yuan from white feather chicken seedlings in April, with a year-on-year decrease of 7.28% [20] Group 7 - Qujiang Cultural Tourism's controlling shareholder's 12 million shares are set to be auctioned due to contractual disputes, representing 4.70% of the total share capital [21] - Duople's shareholder plans to reduce its stake by up to 123,800 shares, accounting for 2% of the total share capital, due to personal funding needs [22][23]

Core Viewpoint - The major shareholder, Hongyun Jiukang Data Technology (Beijing) Co., Ltd., plans to reduce its stake in Jiahe Meikang (Beijing) Technology Co., Ltd. due to liquidity needs, intending to sell up to 1,375,855 shares, which is no more than 1% of the total share capital, within 90 days after the announcement [1][2]. Shareholder Information - As of the announcement date, Hongyun Jiukang holds 9,861,786 shares, representing 7.17% of the total shares of Jiahe Meikang [1][2]. - The shares held by Hongyun Jiukang were acquired prior to the company's initial public offering (IPO) and have been tradable since December 14, 2022 [1]. Reduction Plan Details - The reduction plan will commence 15 trading days after the announcement and will be executed through centralized bidding [1][2]. - The plan is subject to adjustments if the company undergoes any corporate actions such as dividend distributions or stock splits during the reduction period [2]. Historical Reduction Activity - In the past 12 months, Hongyun Jiukang reduced its holdings by 1,788,421 shares at a price of 26.19 yuan per share, which accounted for 1.30% of its total holdings [2]. Compliance and Commitments - The reduction plan aligns with previous commitments made by the major shareholder regarding shareholding changes and complies with relevant regulations [4][5]. - The company confirms that the reduction will not lead to a change in control and will not significantly impact the company's governance or ongoing operations [5].